Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer

Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard)

Immune cell dynamics induced by a single dose of pembrolizumab as revealed by single-cell RNA profiling

Hospitalization and supportive care medication (SCM) utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

SAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer

PALBOCOMP: Retrospective observational analysis of palbociclib treatment in patients with advanced breast cancer within a compassionate use program in Spain

Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

A nationwide, multi-institutional retrospective study of efficacy and safety of eribulin in Korean breast cancer patients (REMARK)

SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Intermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02)

Influence on quality of life of chemotherapy scheduling for patients with advanced HER2-negative breast cancer

Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial

First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)

Utility of early circulating tumour DNA dynamics as a surrogate for progression free survival in the BEECH phase I/II trial in metastatic breast cancer